





Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrev I. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Edward W. Yee Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Tracy L. Muller Juanne M. DeSantis LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timottly A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tang Christopher J. Walsh W. Blake Coblentz*
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Alexandra K. Pechhold
C. Matthew Rozier*
Robert A. Schwartzman
Bryan L. Skelton*
Ulrike Winkler

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurray Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Manrin C. Guthrie

*Admitted only in Maryland

*Admitted only in Virginia

•Practice Limited to
Federal Agencies

February 26, 2007

WRITER'S DIRECT NUMBER: (202) 772-8769 INTERNET ADDRESS: BSKELTON@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Art Unit To be assigned

Attn: Mail Stop Amendment

Re:

U.S. Utility Patent Application

Appl. No. 10/564,511; U.S.C. § 371(c) Date: July 3, 2006 (U.S. Nat'l Phase of Int'l Appln No. PCT/EP2004/007665;

Int'l Filing Date: July 12, 2004)

For:

Hetaryl-Substituted Pyrazolidindione Derivatives with Pesticidal

Characteristics

Inventors: FISCHER et al.

Our Ref: 2400.0170000/JMC/BLS

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement under 37 C.F.R. § 1.97(b);
- 2. Form PTO/SB/08A (6 sheets);
- 3. Form PTO/SB/08B (5 sheets);
- 4. Copies of ninety-two (92) cited references (FP1 FP 48 and NPL1 to NPL44); and
- 5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents February 26, 2007 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Bryan L. Skelton

Attorney for Applicants Registration No. 50,893

BLS/egw Enclosure(s)

646096v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

7

FISCHER et al.

Appl. No.: 10/564,511 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP2004/007665)

§371 Date: July 3, 2006

For: Hetaryl-Substituted

Pyrazolidindione Derivatives with

Pesticidal Characteristics

Confirmation No.: 3449

Art Unit:

To be assigned

Examiner:

To be assigned

Atty. Docket: 2400.0170000/VLC/BLS

Information Disclosure Statement under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents FP1 to FP48 and NPL1 to NPL44 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publication documents, US1 to US3, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3) and MPEP § 609.04(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents, FP1 to FP8, FP10, FP12 to FP14, FP17 to FP19, FP22 to FP23, FP25 to FP27, FP30, FP32 to FP36, FP39, FP41, FP43, FP44, FP46, FP48, NPL1, NPL3, NPL7, NPL9, and NPL16, cited on Forms PTO/SB/ 08A and PTO/SB/08B:

Document FP1, NL 6,614,130, is in the Dutch language. An English language abstract of document FP1 is attached as document NPL26.

n.

- 2 -

Document FP2, DE 1 945 703 A1, is in the German language. An English language abstract of document FP2 is attached as document NPL27.

Document FP3, DE 1 946 370 A1, is in the German language. An English language abstract of document FP3 is attached as document NPL28.

Document FP4, DE 2 218 097 A1, is in the German language. An English language abstract of document FP4 is attached as document NPL29.

Document FP5, DE 2 350 547 A1, is in the German language. An English language abstract of document FP5 is attached as document NPL30.

Document FP6, EP 0 086 750 A2, is in the German language. An English language abstract of document FP6 is attached as document NPL31.

Document FP7, EP 0 094 349 A2, is in the German language. An English language abstract of document FP7 is cited as document NPL32.

Document FP8, EP 0 174 562 A2, is in the German language. An English language abstract of document FP8 is attached as document NPL33.

Document FP10, EP 0 191 736 A2, is in the German language. An English language abstract of document FP10 is attached as document NPL34.

Document FP12, EP 0 269 806 A1, is in the German language. An English language abstract of document FP12 is attached as document NPL35.

Document FP13, EP 0 333 1131 A1, is in the German language. An English language abstract of document FP13 is attached as document NPL36.

Document FP14, EP 0 346 620 A1, is in the German language. An English language abstract of document FP14 is attached as document NPL37.

Document FP17, WO 91/07874 A1, is in the German language. An English language abstract of document FP17 can be found on the face page of the patent.

Document FP18, WO 91/08202 A1, is in the German language. An English language abstract of document FP18 can be found on the face page of the patent.

Document **FP19**, EP 0 492 366 A2, is in the German language. An English language abstract of document FP19 is attached as document **NPL38**.

Document **FP22**, EP 0 528 156 A1, is in the German language. An English language abstract of document FP22 is attached as document **NPL39**.

Document **FP23**, EP 0 582 198 A2, is in the German language. An English language abstract of document FP23 is attached as document **NPL40**.

Document FP25, WO 94/29268 A1, is in the German language. An English language abstract of document FP25 can be found on the face page of the patent.

Document **FP26**, WO 95/07897 A1, is in the German language. An English language abstract of document FP26 can be found on the face page of the patent.

Document FP27, WO 95/18125 A1, is in the Japanese language. An English language abstract of document FP27 can be found on the face page of the patent.

Document FP30, WO 96/35664 A1, is in the German language. An English language abstract of document FP30 can be found on the face page of the patent.

Document FP32, WO 97/01535 A1, is in the German language. An English language abstract of document FP32 can be found on the face page of the patent.

Document FP33, WO 97/02243 A1, is in the German language. An English language abstract of document FP33 can be found on the face page of the patent.

Document FP34, WO 97/36868 A2, is in the German language. An English language abstract of document FP34 can be found on the face page of the patent.

Document FP35, DE 196 21 522 A1, is in the German language. An English language abstract of document FP35 is cited as document NPL42.

Document **FP36**, WO 98/05638 A2, is in the German language. An English language abstract of document FP36 can be found on the face page of the patent.

Document FP39, WO 99/66795 A1, is in the German language. An English language abstract of document FP39 can be found on the face page of the patent.

Document **FP41**, WO 01/17352 A1, is in the German language. An English language abstract of document FP41 can be found on the face page of the patent.

Document **FP43**, WO 01/17972 A2, is in the German language. An English language abstract of document FP43 can be found on the face page of the patent.

Document **FP44**, WO 01/17973 A2, is in the German language. An English language abstract of document FP44 can be found on the face page of the patent.

Document **FP46**, DE 101 52 005 A1, is in the German language. An English language abstract of document **FP46** is attached as document **NPL44**.

Document **FP48**, WO 2005/092897 A2, is in the German language. An English language abstract of document FP48 can be found on the face page of the patent.

Document **NPL1**, Alberola, A., *et al.*, "Reaccion de β-Aminoenonas con Derivados de Hidrazina. Sintesis Regioselectiva de Pirazoles," *An. Quim., Ser. C.* 83:55-61, La Sociedad (1987), is in the Spanish language. An English language abstract of document NPL1 is attached as document **NPL2**.

Document **NPL3**, Asakani, R., "Zur Reaktion von Cyclohexadien-(1.3) mit Azodicarbonsäure-diäthylester," *Chem. Ber.* 98:2551-2555, Verlag Chemie (1965), is in the German language. An English language abstract of document NPL3 is attached as document **NPL4**.

Document NPL7, Dannenberg, V.H. and Dannenberg-von Dresler, D., "Verusche zur Synthese des Steranthrens III," *Justus Liebigs Ann. Chem 585*:1-15, Verlag Chemie (1954), is in the German language. An English language abstract of document NPL7 is attached as document NPL8.

Document NPL9, Diels, V.O., et al., "Über das aus Cyclopentadien und Azoester entestehende Endomethylen-piperidazin und seine Überführung in 1,3-Diaminocyclopentan," *Justus Liebigs Ann. Chem. 443*:242-262, Verlag Chemie (1925), is in the German language. An English language abstract of document NPL9 is attached as document NPL10.

Document NPL16, "Antimicrobial Activity of Compounds in the Series of 5(3)-(2-thienyl) Pyrazole," *Khim.-Farm. Zh.* 8:18-21, Folium Publishing Company (1974), is in the Russian language. An English language abstract of document NPL16 is attached as document NPL17.

Document **FP21** was cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38. The search report is attached as document **NPL25** on the IDS Form, PTO/SB/08B.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Bryan L. Skelton

Attorney for Applicants Registration No. 50,893

Date: FBRURY 26, 7007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

614396v1

no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

6

Complete if Known			
Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)		
§371 Date	July 3, 2006		
First Named Inventor	FISCHER, Reiner		
Art Unit	To be assigned		
Examiner Name	To be assigned		
Attorney Docket Number	2400.0170000/VLC/BLS		

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
unuais	No.	Number-Kind Code ^{2 (If Known)}	WINI-DD-1111	Applican of ched Document	or Relevant Figures Appear
	USI	4,146,721	03/27/1979	Rainer	
	US2	6,235,680 B1	05/22/2001	Ziemer et al.	
	US3	6,251,827 B1	06/26/2001	Ziemer et al.	
	<u> </u>				
	-				+
-		-	-		
			ļ		
					<u> </u>
	ļ				
					
-					
					
-					

		Fo	REIGN PATENT DO	OCUMENTS	
Examiner Cite Initials* No.1		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Country Code ³ Number ⁴ Kind Code ³ (if known)	<u> </u>		T ⁶
	FPI	NL 6,614,130	04/10/1967	Imperial Chemical Industries Limited	Abs
	FP2	DE 1 945 703	07/02/1970	Chas. Pfizer & Co. Inc.	Abs
	FP3	DE 1 946 370	04/22/1971	Byk-Gulden Lomberg Chemische Fabrik GmbH	Abs
	FP4	DE 2 218 097	11/02/1972	Stauffer Chemical Co.	Abs
-	FP5	DE 2 350 547	04/25/1974	Stauffer Chemical Co.	Abs
	FP6	EP 0 086 750 A2	08/24/1983	Ciba-Geigy AG	Abs
	FP7	EP 0 094 349 A2	11/16/1983	Ciba-Geigy AG	Abs
	FP8	EP 0 174 562 A2	03/19/1986	Hoechst Aktiengesellschaft	Abs
	FP9	EP 0 177 353 A2	04/09/1986	Takeda Chemical Industries, Ltd.	

- ·		Doto	
Examine	i	Date	
Signatur		Considered	
1 - 8 - 1 - 1			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute	Substitute for form 1449/PTO		Complete if Known			
INFOR	INFORMATION DISCLOSURE			OCUDE	Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)
	INFORMATION DISCLOSURE				§371 Date	July 3, 2006
STATI				LICANT	First Named Inventor	FISCHER, Reiner
	(Use as many sheets as necessary)			cessary)	Art Unit	To be assigned
					Examiner Name	To be assigned
Sheet	2	of	6		Attorney Docket Number	2400.0170000/VLC/BLS

U.S. PATENT DOCUMENTS					
Examiner Cite Initials No. 1		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
		Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
			- -		
 -	_				-
			1		
				····	
			-		
		-			
			+		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T6	
	FP10	EP 0 191 736 A2	08/20/1986	Ciba-Geigy AG	Abs	
	FP11	WO 87/03807 A1	07/02/1987	Beecham Group P.L.C.		
	FP12	EP 0 269 806 A1	06/08/1988	Hoechst Aktiengesellschaft	Abs	
	FP13	EP 0 333 131 A1	09/20/1989	Hoechst Aktiengesellschaft	Abs	
	FP14	EP 0 346 620 A1	12/20/1989	Hoechst Aktiengesellschaft	Abs	
	FP15	EP 0 368 592 A1	05/16/1990	Imperial Chemical Industries PLC		
	FP16	EP 0 389 699 A1	10/03/1990	Pfizer Inc.		
	FP17	WO 91/07874 A1	06/13/1991	Hoechst Aktiengesellschaft	Abs	
	FP18	WO 91/08202 A1	06/13/1991	Hoechst Aktiengesellschaft	Abs	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449/PTO			Complete	Complete if Known		
INFOF			Neel Ocupe	Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)		
			DISCLOSURE	§371 Date	July 3, 2006		
	STATEMENT BY APPLICANT			First Named Inventor	FISCHER, Reiner		
	(Use as	many she	eets as necessary)	Art Unit	To be assigned		
				Examiner Name	To be assigned		
Sheet	3	of	6	Attorney Docket Number	2400.0170000/VLC/BLS		

			U.S. PATENT DOC		
Examiner Cite Initials No.	Cite	Cite Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,
	NO.	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appea
				- t- A**	
			1	All reserves	
					<u> </u>
			.		
			-		
			-		
	<u> </u>		<u> </u>		

			FOREIGN PATENT DO	DCUMENTS	
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	
Initials*	No.1	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Т6
	FP19	EP 0 492 366 A2	07/01/1992	Hoechst Aktiengesellschaft	Abs
	FP20	WO 92/16510 A1	10/01/1992	Ciba-Geigy AG	
-	FP21	EP 0 508 126 A1	10/14/1992	Bayer AG	ISR
	FP22	EP 0 528 156 A1	02/24/1993	Bayer AG	Abs
	FP23	EP 0 582 198 A2	02/09/1994	Hoechst Aktiengesellschaft	Abs
	FP24	EP 0 613 618 A1	09/07/1994	American Cyanimid Company	
	FP25	WO 94/29268 A1	12/22/1994	Bayer Aktiengesellschaft	Abs
	FP26	WO 95/07897 A1	03/23/1995	Hoechst Schering AgrEvo GmbH	Abs
	FP27	WO 95/18125 A1	07/06/1995	Japan Tobacco Inc.	Abs

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

_	- ,		Onder are	Tapernoni reduction rict or 1950;	persons are required to respond to a conection of information unless it contains a valid Onto contain number		
	Substitute	for form	1449/PT	0	Complete	if Known	
	MEO	38# A 7	rion i		Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)	
l				DISCLOSURE	§371 Date	July 3, 2006	
	STAT			APPLICANT	First Named Inventor	FISCHER, Reiner	
		(Use as	many sh	eets as necessary)	Art Unit	To be assigned	
					Examiner Name	To be assigned	
	Sheet	4	of	6	Attorney Docket Number	2400.0170000/VLC/BLS	

			U.S. PATENT DOC		
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
initiais	NO.	Number-Kind Code ^{2 (If Known)}	WIWI-DD-1111	Applicant of Ched Document	or Relevant Figures Appear
			l		
	<u> </u>				
					-
			<u> </u>		
					
			-		
	<u> </u>		1		

	FOREIGN PATENT DOCUMENTS							
LXaminici Cite Toleign Fatent Document Tableanish Date		Name of Patentee or						
Initials*	No. ¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	T ⁶			
	FP28	WO 96/11574 A1	04/25/1996	Ciba-Geigy AG				
	FP29	WO 96/21652 A1	07/18/1996	Ciba-Geigy AG				
	FP30	WO 96/35664 A1	11/14/1996	Bayer Aktiengesellschaft	Abs			
	FP31	WO 96/37494 A1	11/28/1996	Zeneca Limited				
	FP32	WO 97/01535 A1	01/16/1997	Bayer Aktiengesellschaft	Abs			
	FP33	WO 97/02243 A1	01/23/1997	Bayer Aktiengesellschaft	Abs			
	FP34	WO 97/36868 A1	10/09/1997	Bayer Aktiengesellschaft	Abs			
	FP35	DE 196 21 522 A1	12/04/1997	Hoechst Schering AgrEvo GmbH	Abs			
	FP36	WO 98/05638 A2	02/12/1998	Bayer Aktiengesellschaft	Abs			

Examiner Date Considered	_
--------------------------	---

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Older the Paperwork Reduction Act of 1999, No				to persons are required to respond to a conecar	on or information unless it contains a valid OMB control number	
Substitute i	for form	1449/PT	0	Complete if Known		
INFOR		TION I		Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)	
			DISCLOSURE	§371 Date	July 3, 2006	
			APPLICANT	First Named Inventor	FISCHER, Reiner	
	(Use as	many she	eets as necessary)	Art Unit	To be assigned	
_				Examiner Name	To be assigned	
Sheet	5	of	6	Attorney Docket Number	2400.0170000/VLC/BLS	

			U.S. PATENT DOG	CUMENTS	
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials	No.1	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
				5.0.4	
			ļ		
			-		
			-		
			 		
			-		
			 		
			+		+
			 		
	-				
	-				

			FOREIGN PATENT DO	OCUMENTS -	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	1 %
	FP37	WO 98/25923 A1	06/18/1998	Zeneca Limited	
_	FP38	WO 99/47525 A1	09/23/1999	Novartis AG; Novartis-Erfindungen Verwaltungsgesellschaft MBH	
	FP39	WO 99/66795 A1	12/29/1999	Hoechst Schering AgrEvo GmbH	Abs
	FP40	WO 01/17351 A1	03/15/2001	Syngenta Participations AG	
	FP41	WO 01/17352 A1	03/15/2001	Syngenta Participations AG	Abs
	FP42	WO 01/17353 A1	03/15/2001	Syngenta Participations AG	
	FP43	WO 01/17972 A2	03/15/2001	Syngenta Participations AG	Abs
	FP44	WO 01/17973 A2	03/15/2001	Syngenta Participations AG	Abs
	FP45	WO 03/028466 A2	04/10/2003	Syngenta Participations AG	

Examiner	Da	ate
Signature	Co	onsidered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form	1449/PT0)	Complete	if Known
INIFOR		10N F	NCCI OCUPE	Application Number	10/564,511 (Natl. Phase of PCT/EP2004/007665)
			DISCLOSURE	§371 Date	July 3, 2006
			APPLICANT	First Named Inventor	FISCHER, Reiner
	(Use as	many she	ets as necessary)	Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	6	of	6	Attorney Docket Number	2400.0170000/VLC/BLS

			U.S. PATENT DOC	CUMENTS	
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
untiais	110.	Number-Kind Code ^{2 (If Known)}	WIWIEDD-1111	Applicant of Cited Document	or Relevant Figures Appear
		-			
-			1		
					
				and the second s	
		1			

		ı	FOREIGN PATENT DO	DCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T _e
	FP46	DE 101 52 005 A1	04/30/2003	Bayer CropScience AG	Abs
	FP47	WO 2005/007897 A1	01/27/2005	BLC Leather Technology Centre; The Notthingham Trent University	
	FP48	WO 2005/092897 A2	10/06/2005	Bayer CropScience AG	Abs
	-				

613114v1

Examiner	Date Considered	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Red re required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known				
Application Number	10/564,511 (U.S. Nat'l Phase of Appl. No. PCT/EP2004.007665)			
§371 Date	July 3, 2006			
First Named Inventor	FISCHER, Reiner			
Art Unit	To be assigned			
Examiner Name	To be assigned			
Attorney Docket Number	2400.0170000/VLC/BLS			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Alberola, A., et al., "Reaccion de β-Aminoenonas con Derivados de Hidrazina. Sintesis Regioselectiva de Pirazoles," An. Quim., Ser. C. 83:55-61, La Sociedad (1987)	Abs
	NPL2	STNEasy Database, Accession No. 1988:150363, English language abstract for Alberola, A., "Reaction of beta-aminoenones with hydrazine derivatives. Regioselective synthesis of pyrazoles," An. Quim., Ser. C. 83:55-61, (1987)	
	NPL3	Asakani, R., "Zur Reaktion von Cyclohexadien-(1.3) mit Azodicarbonsäure-diäthylester," <i>Chem. Ber.</i> 98:2551-2555, Verlag Chemie (1965)	Abs
	NPL4	STNEasy Database, Accession No. 1965:463065, English language abstract for Askani, R., "Reaction of 1,3-cyclohexadiene with azodicarboxylic acid diethyl ester," <i>Chem. Berichte.</i> 98:2551-2555, Verlag Chemie (1965)	
	NPL5	Baciocchi, E., "Dimethyl Arylmalonates from Cerium (IV) Ammonium Nitrate Promoted Reactions of Dimethyl Malonate with Aromatic Compounds in Methanol, Tetrahedron Lett. 27:2763-2766, Elsevier (1986)	
	NPL6	Collins, J.L., et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR, Agonists. 2. Structure—Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety," J. Med. Chem. 41:5037-5054, American Chemical Society (1998)	
	NPL7	Dannenberg, V.H. and Dannenberg-von Dresler, D., "Verusche zur Synthese des Steranthrens III," <i>Justus Liebigs Ann. Chem.</i> 585:1-15, Verlag Chemie (1954)	Ab
	NPL8	STNEasy Database, Accession No. 1955:56638, English language abstract for Dannenberg, H. and Dannenberg-Von Dresler, D., "Synthesis of steranthrenes. III. 3,4-Aceperinaphthane and 6,7-aceperinaphtane," <i>Ann. Chem.</i> 585:1-15, Verla Chemie (1954)	
	NPL9	Diels, V.O., et al., "Über das aus Cyclopentadien und Azoester entestehende Endomethylen-piperidazin und seine Überführung in 1,3-Diamino-cyclopentan," <i>Justus Liebigs Ann. Chem.</i> 443:242-262, Verlag Chemie (1925)	Ab

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not the Conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nu

Substitute for form 1449/PTO				Con	Complete if Known		
		D.100		Application Number	10/564,511 (U.S. Nat'l Phase of Appl. No. PCT/EP2004.007665)		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				§371 Date	July 3, 2006		
				First Named Inventor	FISCHER, Reiner		
	(Use as many sheets as necessary)			Art Unit	To be assigned		
		Examiner Name	To be assigned				
Sheet	2	of	5	Attorney Docket Number	2400.0170000/VLC/BLS		

F	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Examiner Initials*	No.1	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL10	STNEasy Database, Accession No. 1925:19216, English language abstract for Diels, O., et al., "The endo-methylenepiperidazine resulting from cyclopentadiene and azo ester and its transformation diaminocyclopentane," <i>Ann. Chem.</i> 443:242-262, Verlag Chemie (1925)	
	NPL11	Ebeid, M.Y., et al., "Synthesis and Biological Activity of Some New 5-Nitrothiazole Derivatives," Egypt. J. Pharm. Sci. 33:99-110, National Information and Documentation Centre Cairo (1992)	
	NPL12	Hulin, B., et al., "Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents," J. Med. Chem. 35:1853-1864. American Chemical Society (1992)	
,	NPL13	Ikeda, Y., et al., "Syntheses and Biological Activities of Some Dithiolanylidenemalonate Derivatives and Related Compounds," J. Fac. Agr. Kyushu Univ. 37:81-92, Faculty of Agric Publications – Kyushu University (1992)	
	NPL14	Kandeel, M. M., "Synthesis of 4-substituted 3-methyl-1-phenyl-2-pyrazoline-5-thiones by heterocycles," <i>Bull. Soc. Chim. Fr., Issue 6</i> :1005-1008, Societe Francaise De Chimie (1988)	
	NPL15	Kulikova, L.K. and Cherkesova, L.V., "Antimicrobial Activity of Compounds in the Series of 5(3)-(2-thienyl) Pyrazole," <i>KhimFarm. Zh.</i> 8:18-21, Folium Publishing Company (1974)	Abs
	NPL16	STNEasy Database, Accession No. 1974:437505, English language abstract for Kulikova, L.K. and Cherkesova, L.V., "Antimicrobial Activity of Compounds in the Series of 5(3)-(2-thienyl) Pyrazole," <i>KhimFarm. Zh.</i> 8:18-21, Folium Publishing Company (1974)	
	NPL17	Malamas, M.S., et al., "Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase," J. Med. Chem. 39:237-245, American Chemical Society (1996)	
	NPL18	Meguro, K., "Studies on Antidiabetic Agents. VII. Synthesis and Hypoglycemic Activity of 4-Oxazoleacetic Acid Derivatives," <i>Chem. Pharm. Bull.</i> 34:2840-2851, Pharmaceutical Society of Japan (1986)	
	NPL19	Nakanishi, S. and Butler, K., "Synthesis of Chlorocarbonyl Ketenes," Org. Prep. Proced. Int. 7:155-158, Organic Preparations and Procedures, Inc. (1975)	

Examiner	Date	- 11
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/564,511 (U.S. Nat'l Phase of Appl. No. PCT/EP2004.007665)	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				§371 Date	July 3, 2006	
				First Named Inventor	FISCHER, Reiner	
(U	se as many	sheets a	s necessary)	Art Unit	To be assigned	
		Examiner Name	To be assigned			
Sheet	3	of	5	Attorney Docket Number	2400.0170000/VLC/BLS	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²		
	NPL20 Nam, N.L., et al., "Simple Method for the Synthesis of 3,5-Dimethylpyrazolyl-1-Ace Acid," Chemistry of Heterocylic Compounds 34:382, Plenum Publishing Corporati (1998)				
	NPL21	Rooney, C.S., et al., "Inhibitors of Glycolic Oxidase. 4-Substited 3-Hydroxy-1 <i>H</i> -pyrrole-2,5-dione Derivatives," <i>J. Med. Chem.</i> 26:700-714, American Chemical Society (1983)			
	NPL22	Scheiblich, S., et al., "Bis-pyrimidylpyrazolinones – a new class of acetohydroxy-acid synthase (AHAS) inhibitor," <i>Pestic. Sci.</i> 55:633-675, Wiley And Sons (1999)			
	NPL23	Seki, M., et al., "Synthesis of 5-Alkyl-4-oxazoleacetic Acid Derivatives with Hypolipidemic Activities," Chem. Pharm. Bull. 36:4435-4440, Pharmaceutical Society of Japan (1988)			
	NPL24	Youssef, M.S.K., "Synthesis of 1-(2,4-Dinitrophenyl)-3-methyl4-substituted Heterocycles-2-pyrazolin-5-one," <i>Z. Naturforcsch. B 39</i> :86-89, Verlag Der Zeitschrift Fur Naturforschung (1983)			
	NPL25	International Search Report for International Application No. PCT/EP2004/007665, European Patent Office, Netherlands, mailed on December 28, 2004	: 		
	NPL26	Dialog File 351, Accession No. 124723, Derwent WPI English language abstract for NL 6,614,130 (listed on accompanying PTO/SB/08A as document FP1)			
	NPL27	Dialog File 351, Accession No. 288927, Derwent WPI English language abstract for DE 1 945 703 A1 (listed on accompanying PTO/SB/08A as document FP2)			
	NPL28	Dialog File 351, Accession No. 369741, Derwent WPI English language abstract for DE 1 946 370 (listed on accompanying PTO/SB/08A as document FP3)			
	NPL29	Dialog File 351, Accession No. 502720, Derwent WPI English language abstract for DE 2 218 097 A1 (listed on accompanying PTO/SB/08A as document FP4)			

Examiner	Date	
Signature	Considered	
1 -		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Co.	Complete if Known		
	Application Number	10/564,511 (U.S. Nat'l Phase of Appl. No. PCT/EP2004.007665)		
INFORMATION DISCLOSURE	§371 Date	July 3, 2006		
STATEMENT BY APPLICANT	First Named Inventor	FISCHER, Reiner		
(Use as many sheets as necessary)	Art Unit	To be assigned		
	Examiner Name	To be assigned		
Sheet 4 of 5	Attorney Docket Number	2400.0170000/VLC/BLS		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL30	Dialog File 351, Accession No. 629712, Derwent WPI English language abstract for DE 2 350 547 A1 (listed on accompanying PTO/SB/08A as document FP6)	
	NPL31	Dialog File 351, Accession No. 2714950, Derwent WPI English language abstract for EP 0 086 750 A2 (listed on accompanying PTO/SB/08A as document FP7)	
	NPL32	Dialog File 351, Accession No. 2777922, Derwent WPI English language abstract for EP 0 094 349 A2 (listed on accompanying PTO/SB/08A as document FP8)	i
	NPL33	Dialog File 351, Accession No. 3892231, Derwent WPI English language abstract for EP 0 174 562 A2 (listed on accompanying PTO/SB/08A as document FP9)	
	NPL34	Dialog File 351, Accession No. 3770049, Derwent WPI English language abstract for EP 0 191 736 A2 (listed on accompanying PTO/SB/08A as document FP10)	
	NPL35	Dialog File 351, Accession No. 4372286, Derwent WPI English language abstract for EP 0 269 806 A1 (listed on accompanying PTO/SB/08A as document FP13)	
	NPL36	Dialog File 351, Accession No. 4889149, Derwent WPI English language abstract for EP 0 333 131 A1 (listed on accompanying PTO/SB/08A as document FP14)	
	NPL37	Dialog File 351, Accession No. 4963457, Derwent WPI English language abstract for EP 0 346 620 A1 (listed on accompanying PTO/SB/08A as document FP15)	
,	NPL38	Dialog File 351, Accession No. 5984812, Derwent WPI English language abstract for EP 0 492 366 A2 (listed on accompanying PTO/SB/08A as document FP20)	
	NPL39	Dialog File 351, Accession No. 6602040, Derwent WPI English language abstract for EP 0 528 156 (listed on accompanying PTO/SB/08A as document FP23)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
IN EODIE		2122		Application Number	10/564,511 (U.S. Nat'l Phase of Appl. No. PCT/EP2004.007665)	
			LOSURE	§371 Date	July 3, 2006	
STATEMENT BY APPLICANT				First Named Inventor	FISCHER, Reiner	
((Use as many	sheets a	s necessary)	Art Unit	To be assigned	
				Examiner Name	To be assigned	
Sheet	5	of	5	Attorney Docket Number	2400.0170000/VLC/BLS	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		
	NPL40	Dialog File 351, Accession No. 6665683, Derwent WPI English language abstract for EP 0 582 198 A2 (listed on accompanying PTO/SB/08A as document FP24)		
	NPL41	Dialog File 351, Accession No. 8440872, Derwent WPI English language abstract for WO 96/35664(listed on accompanying PTO/SB/08A as document FP31)		
	NPL42	Dialog File 351, Accession No. 9053979, Derwent WPI English language abstract for DE 196 21 522 A1 (listed on accompanying PTO/SB/08A as document FP36)		
	NPL43	Dialog File 351, Accession No. 9060886, Derwent WPI English language abstract for WO 98/05638 (listed on accompanying PTO/SB/08A as document FP37)		
	NPL44	Dialog File 351, Accession No. 13822137, Derwent WPI English language abstract for DE 101 52 005 (listed on accompanying PTO/SB/08A as document FP47)		
	**			
	:			

612832v1

Examiner	Date	
Signature	Considered	
_		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{**}EXAMINER: Initial if reference considered, whether of not claim is in conformance with MPEP 609. Draw line through claim in the first considered include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.